At an unusually quiet annual meeting of the American Society of Clinical Oncology, Joanne Lager and Israel Lowy, the oncology heads of Sanofi (Euronext: SAN) an 12 June 2017
As the annual meeting of the American Society of Clinical Oncology gets underway in Chicago, investors, competitors and industry watchers eagerly await results 2 June 2017
Germany’s Merck KGaA has not appeared near the summit of any rankings on top pharma companies by oncology revenue in recent years, with earnings from its sole c 31 May 2017
Speaking with The Pharma Letter ahead of the upcoming annual meeting of the American Society of Clinical Oncology, Michael Pehl says that: “We are really excite 26 May 2017
While drug developers deserve credit for the enormous progress achieved in hepatology, use of the word ‘cured’ can perhaps be seen as unhelpful given that globa 22 May 2017
Unusually for a biotech leader, chief executive Steve Holcombe had no previous experience or training in the life sciences when he joined vTv Therapeutics. 24 April 2017
When faced with criticism over drug prices, pharma companies can point to figures which reveal how little of countries’ healthcare budgets go towards prescripti 13 April 2017
When Swedish Orphan Biovitrum announced its financial results in February, all eyes were on the Stockholm-based firm’s hemophilia portfolio. 12 April 2017
The chief executive for the UK and Ireland at German pharma major Bayer (BAYN: DE) is spending 30% of his time working on issues related to Brexit, he said this 1 April 2017
Before Theresa May signed the decree absolute, Ireland began preparing its bid to become the new home of the European Medicines Agency (EMA). 29 March 2017
As senior vice president for the global business franchise fertility at German pharma major Merck KGaA, Dorothea Wenzel has been tasked with deciding what to do 22 March 2017
The chance to focus on an area of massive unmet medical need was a major factor in attracting Gabriel Baertschi to leave his previous role as president and gene 7 March 2017
“A focused strategy but one that’s diverse within the areas of focus that we have” sums up the approach of Bayer (BAYN: DE) and Robert LaCaze in oncology as the 2 March 2017
Ovid’s metamorphosis from fledgling biotech startup to global rare disease specialist with epic ambitions.began just two years ago with $5 million in venture ca 28 February 2017
Isabel Torres, global head for access to medicine at Japanese pharma major Takeda Pharmaceutical, tells The Pharma Letter about its Access to Medicine (AtM) str 17 February 2017
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.